A special form of lycopene called lycosome-formulated lycopene, taken as a 7 mg daily supplement for 30 days, is linked to a threefold decrease in markers of inflammatory oxidative damage in people with coronary artery disease. In contrast, another form, lactolycopene, does not show a significant effect.
See the scientific wording
Consumption of lycosome-formulated lycopene at a dose of 7 mg daily for 30 days is associated with a threefold reduction in inflammatory oxidative damage markers in patients with coronary vascular disease, whereas lactolycopene has no significant effect.
Very strong evidence
Randomized trialsOne moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Randomized Controlled TrialHuman2018
The study tested the same supplement and found it reduced markers of inflammation and oxidation by three times, just as the claim says, while the other form of lycopene did nothing.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Lycopene is a powerful antioxidant, but regular lycopene is poorly absorbed by the body. The lycosome formulation wraps lycopene in tiny fat particles, making it much easier for the gut to absorb into the blood. Once in the blood, lycopene neutralizes harmful free radicals that damage fats and proteins, lowering markers of oxidative damage. Lower oxidative stress reduces inflammation and improves the ability of blood vessels to widen and deliver oxygen to tissues. This cascade leads to a threefold reduction in inflammatory oxidative damage markers.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
A special form of lycopene called lycosome-formulated lycopene, taken as a 7 mg daily supplement for 30 days, is linked to a threefold decrease in markers of inflammatory oxidative damage in people with coronary artery disease. In contrast, another form, lactolycopene, does not show a significant effect.
Mechanism
1 studyLycosome-formulated lycopene gets into the blood much better than regular lycopene. Once in the blood, it neutralizes damaging free radicals, lowering oxidative stress and inflammation. This helps blood vessels work better and deliver more oxygen to tissues, which cuts inflammatory oxidative damage by three times.
Lycopene is a powerful antioxidant, but regular lycopene is poorly absorbed by the body. The lycosome formulation wraps lycopene in tiny fat particles, making it much easier for the gut to absorb into the blood. Once in the blood, lycopene neutralizes harmful free radicals that damage fats and proteins, lowering markers of oxidative damage. Lower oxidative stress reduces inflammation and improves the ability of blood vessels to widen and deliver oxygen to tissues. This cascade leads to a threefold reduction in inflammatory oxidative damage markers.
Lycosome formulation encapsulates lycopene to enhance its intestinal absorption and protect it from degradation, leading to a significant increase in serum lycopene levels.
Elevated circulating lycopene scavenges free radicals, reducing oxidative damage to lipids and other biomolecules, as evidenced by decreased oxidized LDL and inflammatory oxidative damage (IOD).
Reduced oxidative stress attenuates inflammatory responses, indicated by decreased levels of Chlamydia pneumoniae IgG, a marker of chronic inflammation.
Lower oxidative stress and inflammation improve endothelial function and tissue oxygenation, reflected by increased flow-mediated dilation (FMD) and tissue oxygen saturation (StO2).
Evidence from Studies
Supporting (1)
Community contributions welcome
Effect of lycopene supplementation on cardiovascular parameters and markers of inflammation and oxidation in patients with coronary vascular disease
The study tested the same supplement and found it reduced markers of inflammation and oxidation by three times, just as the claim says, while the other form of lycopene did nothing.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review of Lycopene Formulations on Inflammatory Markers in CVD Patients
Systematic review and meta-analysis of randomized controlled trials involving CVD patients supplemented with lycosome-formulated lycopene (7 mg daily for 30 days) compared to placebo or lactolycopene, measuring inflammatory oxidative damage markers at baseline and post-intervention.
Double-Blind RCT of Lycosome-Formulated Lycopene vs. Lactolycopene vs. Placebo in CVD Patients
Double-blind, placebo-controlled, parallel-group RCT with three arms: lycosome-formulated lycopene (7 mg daily), lactolycopene (7 mg daily), and placebo, for 30 days. Inclusion: patients with documented coronary vascular disease. Primary outcome: change in inflammatory oxidative damage markers (e.g., MDA, oxLDL, 8-OHdG).
Prospective Cohort Study of Dietary Lycopene Intake and Inflammatory Markers in CVD Patients
Prospective cohort of patients with coronary vascular disease followed for at least 30 days. Exposure: self-reported use of lycosome-formulated lycopene supplements (7 mg daily) or dietary lycopene intake. Outcome: levels of inflammatory oxidative damage markers measured at baseline and follow-up. Adjust for confounders.
In Vitro Comparison of Lycosome-Formulated Lycopene vs. Lactolycopene on Oxidative Stress in Endothelial Cells
Human coronary artery endothelial cells (HCAECs) exposed to oxidized LDL to induce oxidative stress. Treatment with lycosome-formulated lycopene, lactolycopene, or vehicle control at relevant concentrations. Measure markers of oxidative damage (e.g., ROS, MDA, 8-isoprostane) and cell viability.